Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Cash & Current Investments: 2010-2025

Historic Cash & Current Investments for Anika Therapeutics (ANIK) over the last 16 years, with Sep 2025 value amounting to $80.2 million.

  • Anika Therapeutics' Cash & Current Investments fell 11.63% to $80.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $311.9 million, marking a year-over-year decrease of 18.60%. This contributed to the annual value of $79.2 million for FY2024, which is 16.70% down from last year.
  • According to the latest figures from Q3 2025, Anika Therapeutics' Cash & Current Investments is $80.2 million, which was up 3.96% from $77.1 million recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' Cash & Current Investments ranged from a high of $124.2 million in Q4 2021 and a low of $75.4 million during Q1 2025.
  • In the last 3 years, Anika Therapeutics' Cash & Current Investments had a median value of $95.1 million in 2023 and averaged $92.0 million.
  • As far as peak fluctuations go, Anika Therapeutics' Cash & Current Investments crashed by 32.69% in 2021, and later soared by 34.04% in 2022.
  • Quarterly analysis of 5 years shows Anika Therapeutics' Cash & Current Investments stood at $124.2 million in 2021, then decreased by 2.64% to $121.0 million in 2022, then decreased by 21.38% to $95.1 million in 2023, then decreased by 16.70% to $79.2 million in 2024, then dropped by 11.63% to $80.2 million in 2025.
  • Its last three reported values are $80.2 million in Q3 2025, $77.1 million for Q2 2025, and $75.4 million during Q1 2025.